Diclofenac/misoprostol: The european clinical experience

Journal of Rheumatology

Volumn 25, Issue SUPPL. 51, 1998, Pages 21-30

  McKenna, Frank ^a  

^a TRAFFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

ARTHROTEC ; DICLOFENAC; ENDOSCOPY MISOPROSTOL; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS

Indexed keywords

ANTIRHEUMATIC AGENT; ARTHROTEC; DICLOFENAC; IBUPROFEN; INDOMETACIN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ANTIULCER AGENT;

ABDOMINAL PAIN; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG MIXTURE; DRUG TOLERABILITY; DYSPEPSIA; ENTERIC COATED TABLET; GASTRODUODENAL ULCER; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; DUODENOSCOPY; DUODENUM ULCER; GASTROSCOPY; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; DICLOFENAC; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DUODENAL ULCER; DUODENOSCOPY; GASTROSCOPY; HUMANS; MISOPROSTOL; NAPROXEN; OSTEOARTHRITIS; PIROXICAM; STOMACH ULCER;

EID: 0031920605     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis, part I: osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40.
2. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis, part II: osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6.
3. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
4. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure; cohort study. BMJ 1997;315:1333-7.
5. Silvoso G, Ivey KJ, Butt J, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979;91:517-20.
6. Lockard OO, Ivey KY, Butt JH, et al. The prevalence of duodenal lesions in patients with rheumatic disease on chronic aspirin therapy. Gastrointest Endosc 1980;26:5-7.
7. Trondstad RI, Aaadland E, Holler T, Olaussen B. Gastroscopic findings after treatment with enteric-coated and plain naproxen tablets in healthy subjects. Scand J Gastroenterol 1985;20:239-42.
8. Hansen TM, Matzen P, Madsen P. Endoscopic evaluation of the effect of indomethacin capsules and suppositories on the gastric mucosa in rheumatic patients. J Rheumatol 1984;11:484-7.
9. Graham DY, Smith JL, Holmes GI, et al. Nonsteroidal antiinflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther 1985;38:65-70.
10. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of non-steroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991;115:195-200.
11. Ehsanullah RSB, Page MD, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial with ranitidine. BMJ 1988;297:1017-21.
12. Robinson MG, Griffin JW, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci 1989;34:424-8.
13. Oddsson E, Gudjonnsson H, Thjodleifsson B. Protective effect of omeprazole or ranitidine against naproxen-induced damage to the human gastroduodenal mucosa [abstract]. Scand J Gastroenterol 1990;25 Suppl 76:13.
14. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAID. Ann Intern Med 1993;119:257-62.
15. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:344-50.
16. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
17. Agrawal NM, Van Kerckhove HEJM, Erhardt LJ, Geis GS. Misoprostol coadministered with diclofenac for the prevention of gastroduodenal ulcers. A one-year study. Dig Dis Sci 1995;40: 1125-31.
18. ® Investigators' Meeting Highlights. Princeton, NJ: Excerpta Medica; 1992:30-4.
19. Doherty M. The efficacy of Arthrotec in the treatment of osteoarthritis. Scand J Rheumatol 1992; Suppl 96:15-21.
20. ® Investigators' Meeting Highlights. Princeton, NJ: Excerpta Medica; 1992:24-9.
21. A comparison of diclofenac/misoprostol and diclofenac/placebo in the treatment of rheumatoid arthritis. Data on file, G.D. Searle & Co., Skokie, IL. Report IN2-90-06-292; September 5, 1990.
22. Kiff PS, Stead H, Morant V, Shield MJ. Arthrotec, diclofenac, and ibuprofen in general practice. Eur J Rheumatol 1994;14 Suppl 3:31-8.
23. Verdickt W, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostrol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992;21: 85-91.
24. Bolten W, Melo Gomes JA, Stead H, Geis GS. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992;31:753-8.
25. Melo Gomes JA, Roth SH, Bruyn GAW, Woods EM, Geis GS. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993;52:881-5.
26. McKenna F, Allan L, Kiff PS. Diclofenac/misoprostol and indomethacin: efficacy and GI damage in rheumatoid arthritis and ankylosing spondylitis [abstract]. Rheumatol Eur 1995;24 Suppl 3:220.
27. Stead H, Morant SV,. Shield MJ. The combination drug diclofenac 75 mg/misoprostol 200 μg provides equivalent antiarthritic efficacy to diclofenac 75 mg SR in RA and OA but with an improved safety profile [abstract]. Rheumatol Eur 1996;25 Suppl 1:46.
28. Report of a randomised, blinded three-month study in patients with rheumatoid arthritis or osteoarthritis, in which diclofenac 75 mg slow release and the combination tablet diclofenac 75 mg/ misoprostol 200 μg (Arthrotec 75), both administered twice a day, were compared for antiarthritic efficacy, tolerability and incidence of endoscopically detected upper GI damage. Data on file, G.D. Searle & Co., Skokie, IL. Report 188-96-06-013; April 30, 1996.
29. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic ulcer disease. N Engl J Med 1974;290:1158-62.
30. Peoples B. Peptic ulcer disease and the nonsteroidal anti-inflammatory drugs. Am Surg 1985;51:358-62.
31. Collier DSJ, Pain JA. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut 1985;26:359-63.
32. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987;28:527-32.
33. Garner A, Allen A, Rowe PH. Gastroduodenal mucosal defense mechanisms and the action of non-steroidal anti-inflammatory agents. Scand J Gastroenterol 1987;22 Suppl 127:29S-34S.
34. Fromm D. How do non-steroidal anti-inflammatory drugs affect gastric mucosal defenses? Clin Invest Med 1987;10:251-8.
35. Domschke S, Domschke W. Gastroduodenal damage due to drugs, alcohol, and smoking. Clin Gastroenterol 1984;13:405-36.
36. Szabo S. Mechanisms of mucosal injury in the stomach and duodenum: time-sequence analysis of morphologic, functional, biochemical, and histochemical studies. Scand J Gastroenterol 1987;22 Suppl 127:21S-28S.
37. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979;77:761-7.
38. Konturek SJ, Piastucki I, Brzozowski T. et al. Role of prostaglandins in the formation of aspirin-induced gastric ulcers. Gastroenterology 1981:80:4-9.
39. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983;245:G601-G623.
40. Isenberg JI, Hogan DL, Selling JA, Koss MA. Duodenal bicarbonate secretion in humans: role of prostaglandins [abstract]. Dig Dis Sci 1986;31:130S.
41. Soll AH. Review: antisecretory drugs - cellular mechanisms of action. Aliment Pharmacol Ther 1987;1:77-89.
42. Cohen MM. Role of endogenous prostaglandins in gastric secretion and mucosal defense. Clin Invest Med 1987;10:226-31.
43. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988;2:1277-80.
44. Agrawal NM, Roth S, Graham DY, et al. Comparison of misoprostol and sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991;115:195-200.
45. Graham DY, Whitehead RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAID. Ann Intern Med 1993;119:257-62.
46. Elliott SL, Yeomans ND, Buchanan RR, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo-controlled trial. Scand J Rheumatol 1994;23:171-6.
47. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1988;35:244-85.
48. Skoutakis VA, Carter CA, Mickle TR, et al. Review of diclofenac and evaluation of its place in therapy as a nonsteroidal anti-inflammatory agent. Drug Intell Clin Pharm 1988;22:850-9.
49. Ivey KJ. Pathophysiology of NSAID-induced gastroduodenal damage: epidemiology and mechanisms of action of therapeutic agents. Aliment Pharmacol Ther 1991;5 Suppl 1:91-8.
50. ® (diclofenac sodium) prescribing information. Physicians' Desk Reference. 50th ed. Montvale, NJ: Medical Economics Company; 1996:861-4.